- Home
- ONCY vs CGTX Comparison
ONCY vs CGTX Comparison
Compare ONCY & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCY | CGTX |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.0M | 94.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ONCY | CGTX |
|---|---|---|
| Price | $0.97 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $6.00 | $3.33 |
| AVG Volume (30 Days) | ★ 2.1M | 941.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.22 |
| 52 Week High | $1.51 | $3.83 |
Technical Indicators
Market Signals| Indicator | ONCY | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 42.36 |
| Support Level | $0.79 | $1.05 |
| Resistance Level | $1.10 | $1.21 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 48.58 | 41.67 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.